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Introduction
Notch signaling between neighboring cells critically controls cell 
fate decisions in all metazoans (1, 2). In mammalian cells, engage-
ment of the Notch receptors (Notch1–4) by the ligands (Jagged1 
and -2 and Delta-like 1, -3, and -4) triggers sequential proteolysis 
of the receptors, which culminates in intramembranous cleavages 
by the γ-secretase complex and results in release of the Notch 
intracellular domain (NICD) (3–5). In the best-studied “canon-
ical” mechanism, NICD released from the plasma membrane 
translocates to the nucleus, where it interacts with the transcrip-
tion factor RBPjk and a mastermind-like transcriptional coacti-
vator (Maml1–3) to activate the transcription of target genes (6). 
Among the best known targets of Notch signaling are the Hes/
Hey family of basic helix-loop-helix (bHLH) transcription repres-
sors (7). However, the regulation of individual Hes/Hey proteins 
by Notch and their role in mediating Notch function are highly 
dependent on cell context.
Mouse genetic studies have uncovered important functions 
for Notch signaling in bone. Genetic deletion of either the γ-secre-
tase catalytic subunits presenilin 1 and -2, or Notch1 and -2 in the 
embryonic limb mesenchyme results in excessive osteoblast dif-
ferentiation at the expense of bone marrow mesenchymal progen-
itors (8). More recently, specific deletion of Notch2 in early-stage 
osteoblast lineage cells with Runx2-Cre increased trabecular bone 
mass in a site-specific manner (9). In addition, Jagged1 appears to 
be a major ligand in the maintenance of the osteoprogenitor pool 
(10). Consistent with the negative role of Notch in osteoblast dif-
ferentiation, forced expression of NICD in osteoblastic precursors 
reduced osteoblast numbers and caused osteopenia (11). Intrigu-
ingly, forced expression of NICD at a later stage of the osteoblast 
lineage led to sclerosis owing to excessive proliferation of the 
immature osteoblasts, highlighting stage-specific functions of 
constitutive Notch activation in the osteoblast lineage (12). Abnor-
mal Notch activation in mesenchymal progenitors has also been 
implicated in decreased osteoblast differentiation associated 
with rheumatoid arthritis (13). In keeping with the mouse studies, 
Notch1 haploinsufficiency in humans causes ectopic osteoblast 
differentiation and calcification in the aortic valves (14, 15), where-
as Notch2 stabilizing mutations are responsible for Hadju-Cheney 
syndrome (HCS), a disorder of severe and progressive bone loss 
(16, 17). Mice carrying an HCS mutation knockin allele through 
the germ line developed severe osteopenia due to increased bone 
resorption (18). More recently, a mouse strain expressing a condi-
tional Notch2-knockin allele lacking the PEST degradation signal 
was created, and activation of the allele specifically in osteoblasts 
resulted in osteopenia due to increased Rankl expression, which 
promotes osteoclastogenesis (19). In all cases, however, the mech-
anisms through which Notch signaling inhibits osteoblast differ-
entiation from the progenitors have not been fully elucidated.
Recent studies have implicated the rewiring of cellular 
metabolism in osteoblast differentiation. In particular, Wnt/
Lrp5 signaling, which promotes bone formation in both mice 
and humans, has been shown to stimulate aerobic glycolysis 
and glutamine catabolism as well as fatty acid oxidation during 
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pressing metabolism through the TCA cycle (27). However, in the 
mouse, Notch signaling has been shown to suppress glycolysis in 
endothelial cells (28). Notch activation was also linked with the 
increase in both glycolysis and mitochondrial oxidative phos-
phorylation in murine proinflammatory macrophages (29). Thus, 
it is likely that Notch controls cellular metabolism in a context- 
dependent manner. A potential role for the metabolic regulation 
of Notch in bone has yet to be explored.
Here, we report that Notch signaling diminished glycolysis 
along with suppression of osteoblast differentiation in bone mar-
row mesenchymal progenitors. Deletion of Notch2 concurrently 
increased glycolysis and osteoblast numbers in the mouse. Pharma-
cological reduction of the glycolytic flux abrogated excessive bone 
formation in Notch2-deficient mice. Thus, Notch signaling impedes 
bone formation in part through suppression of glucose metabolism.
osteoblastogenesis (20–22). In addition, teriparatide, a fragment 
(amino acids 1–34) of human parathyroid hormone (PTH) and an 
FDA-approved bone anabolic drug, enhances aerobic glycolysis 
via the induction of insulin-like factor (Igf) signaling (23). Runx2, 
a critical transcription factor for osteoblast differentiation, 
appears to engage Glut1, the major glucose transporter in osteo-
genic cells, in a feed-forward regulation to control osteoblast dif-
ferentiation and bone formation in the mouse (24). Interestingly, 
Notch signaling has been shown to affect cellular metabolism in 
other systems. Both hyper- and hypoactivation of Notch induced 
a glycolytic phenotype in breast cancer cells through distinct 
mechanisms (25). Forced expression of NICD1 in a cell culture 
model altered the mitochondrial proteome involved in oxidative 
phosphorylation, glutamine catabolism, and fatty acid oxidation 
(26). In Drosophila cells, Notch stimulated glycolysis while sup-
Figure 1. Notch signaling suppresses glycolysis in bone marrow mesenchymal progenitors. (A) Relative mRNA levels of the indicated genes assayed by 
RT-qPCR in R26-NICD2 BMSCs infected with Ad-GFP or Ad-Cre and treated with mineralization media for 48 hours. n = 3. (B) AP or von Kossa staining in 
R26-NICD2 BMSCs infected with Ad-GFP or Ad-Cre after 4 days or 2 weeks, respectively, in mineralization media. (C) Glucose consumption and lactate pro-
duction by R26-NICD2 BMSCs infected with Ad-GFP or Ad-CRE in regular growth media for 48 hours. n = 3. (D) Diagram of glycolysis and its key enzymes. 
(E) Western blots in R26-NICD2 BMSCs infected with Ad-GFP or Ad-CRE for 24 or 48 hours. Protein levels were normalized to β-actin and designated 1 in 
samples infected with Ad-GFP. Quantification (mean ± SD) was determined from 3 independent samples. (F) Glucose consumption and lactate production 
from WT BMSCs with or without Jagged1 stimulation for 48 hours. n = 3. (G) Western blots in WT BMSCs with or without Jagged1 stimulation for the indi-
cated durations. Protein levels were normalized to β-actin or tubulin, and quantification (mean ± SD) was determined from 3 independent samples.  
*P < 0.05, by 2-tailed Student’s t test (A, C, and E–G). Hk2: hexokinase 2; Pfkfb3/4: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 or 4; 
F-2,6-P: fructose 2,6-bisphosphate; Pfk1: phosphofructokinase 1; Eno: enolase; Ldha: lactate dehydrogenase a; Pkm: pyruvate kinase, muscle.
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Hey1, Hey2, and Hes1, but markedly suppressed expression of the 
osteoblast markers Alpl, Bsp, Bglap, and Sp7 in BMSCs (Figure 1A). 
After 4 days or 2 weeks of differentiation, the Ad-Cre–infected 
cells showed less alkaline phosphatase (AP) or von Kossa staining, 
respectively, than did the control cells (Figure 1B). Thus, sustained 
Notch2 signaling suppresses osteoblast differentiation from bone 
marrow mesenchymal progenitors.
In light of recent evidence implicating glucose metabo-
lism in osteoblast differentiation, we investigated the effect of 
Notch2 activation on glycolysis. When BMSCs from R26-NICD2 
mice were infected with Ad-Cre or Ad-GFP, those infected with 
Ad-Cre consumed less glucose and secreted less lactate after 48 
hours (Figure 1C). To assess the biochemical basis for the glyco-
lytic suppression, we examined the abundance of several enzymes 
controlling key steps of glycolysis (Figure 1D). Among those, Pfk-
fb3 and Pfkfb4 increase the amount of fructose-2,6-bisphosphate 
(F-2,6-P) that stimulates the activity of phosphofructokinase Pfk1, 
Results
Notch signaling suppresses glycolysis in bone marrow mesenchymal 
progenitors. HCS is caused by abnormal stabilization of the Notch2 
ICD (NICD2) following activation of the Notch2 receptor. The 
increased half-life of NICD2 probably leads to elevated NICD2 lev-
els and a prolonged Notch response in the cell. To model this aspect 
of HCS, we overexpressed NICD2 in primary cultures of bone mar-
row stromal cells (BMSCs). Specifically, we used the R26-NICD2 
mouse, which was genetically engineered to express NICD2 from 
the ubiquitously active Rosa26 locus upon Cre recombination (30). 
Briefly, BMSCs were cultured from young adult mice harboring the 
R26-NICD2 allele and infected with adenovirus expressing either 
Cre (Ad-Cre) or GFP as a control (Ad-GFP). As BMSCs contain 
mesenchymal progenitors with the potential to become osteo-
blasts, we assessed the effect of NICD2 overexpression on osteo-
blastogenesis in response to ascorbic acid and β-glycerophosphate. 
After 48 hours of treatment, NICD2 induced the Notch target genes 
Figure 2. Suppression of glycolysis abolishes excessive bone formation caused by Notch2 deletion. (A) Western blots of long bones from 8-week-old 
Prx1-Cre Notch2fl/fl (PN2) mice and Notch2fl/fl (N2) littermates. Each lane is for a separate mouse. (B) Glucose consumption and lactate production in N2 
and PN2 BMSCs with or without Jagged1 treatment for 48 hours. n = 3. (C–I) Analyses of 7-week-old N2 or PN2 mice that received 3PO or DMSO for 4 weeks 
starting at 3 weeks of age, including body weight (C), blood glucose (D), 14C-2DG uptake in bone (E), μCT images (F), μCT quantification (G), and dynamic 
histomorphometry (H) of trabecular bone in the proximal tibia, as well as serum CTX-I levels (I). n = 3. *P < 0.05, by 2-way ANOVA followed by Bonferroni’s 
post hoc test (C–E, H, and I) or 2-tailed Student’s t test (B and G). BV, bone volume; DPM, disintegrations per minute; TV, total volume. 
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lated in the bones of PN2 mice, 
consistent with reduced Notch 
signaling (31) (Supplemental 
Figure 1). Western blotting 
revealed a notable increase in 
Pfkfb3, Pkm1, Pkm2, and Ldha 
in the bone protein extracts of 
PN2 versus their N2 littermates 
(Figure 2A). To confirm that 
Notch2 was a major receptor 
in suppressing glycolysis, we 
evaluated the effect of Jagged1 
on glycolysis in BMSCs from 
N2 versus those from PN2 mice. While the N2 BMSCs showed an 
obvious decrease in glucose consumption and lactate secretion in 
response to Jagged1, the PN2 BMSCs showed no such response 
(Figure 2B). Thus, Notch2 is a major receptor for mediating the 
suppression of both bone formation and glycolysis in bone cells.
We next assessed whether increased glycolysis contributes 
to the excessive bone formation caused by Notch2 deletion. The 
small molecule 3PO is a cell-permeable inhibitor of Pfkfb3, which 
normally produces 2,6-bisphosphofructose, a potent activator of 
glycolysis (32). We found that treatment of mice with 3PO for 1 
month did not significantly change their body weights or cause any 
obvious distress to the mice (Figure 2C). Treatment with 3PO also 
did not impair glucose homeostasis, as indicated by the normal 
fasting blood glucose levels in the mice (Figure 2D). To monitor the 
potential effect of Notch2 deletion or 3PO on glucose metabolism 
in bone, we performed glucose uptake assays in vivo by injecting 
14C-labeled 2-deoxyglucose (2-DG). The results showed a clear 
increase in 2-DG uptake in the bones of PN2 mice compared with 
uptake in N2 mice under the control conditions (DMSO injection). 
Moreover, the month-long 3PO treatment significantly reduced 
2-DG uptake in the bones of both PN2 and N2 mice (Figure 2E). 
Importantly, 3PO significantly reduced the cancellous bone mass 
in both N2 and PN2 mice (Figure 2F). As a result, 3PO completely 
abolished the high-bone-mass phenotype in PN2 mice and ren-
dered the cancellous bone mass indistinguishable between the 2 
genotypes (Figure 2G and Table 1). 3PO also reduced cortical bone 
volume without affecting tissue volume in both N2 and PN2 mice 
(Table 2). Dynamic histomorphometry revealed that 3PO reduced 
both the mineral apposite rate (MAR) and the mineralizing surface 
over bone surface (MS/BS) percentage, regardless of genotype, 
thereby completely eliminating the significant increase in bone for-
mation rate over bone surface (BFR/BS) caused by Notch2 deletion 
whereas Ldha helps to sustain glycolysis by regenerating NAD+, 
while converting pyruvate to lactate. Infection of the BMSCs with 
Ad-Cre notably reduced Pfkfb3 and Pfkfb4 after 24 or 48 hours 
and also decreased Ldha levels after 48 hours (Figure 1E). Thus, 
Notch2 activation concurrently suppresses glycolysis and osteo-
blast differentiation in bone marrow mesenchymal progenitors.
To corroborate the metabolic regulation by Notch signaling, 
we activated the pathway in WT BMSCs with recombinant Jag-
ged1 immobilized on the culture dish. After 48 hours of culture, 
we found that Jagged1 suppressed glucose consumption and lac-
tate secretion when compared with the control Fc (Figure 1F). 
Biochemically, Jagged1 reduced the abundance of Pfkfb3, Pfkfb4, 
and Ldha after 24 or 48 hours of culture (Figure 1G). In addition, 
after 48 hours, Jagged1 suppressed the pyruvate kinases Pkm1 and 
Pkm2 that control the last step of glycolysis, without affecting the 
hexokinase Hk2 (Figure 1G). Thus, as with Notch2 overexpression, 
Notch activation by Jagged1 suppresses glycolysis in bone marrow 
mesenchymal progenitors.
Suppression of glycolysis abolishes the excessive bone forma-
tion caused by Notch2 deletion. We next tested the contribution 
of glycolysis to the effect of Notch signaling on bone formation. 
We have previously demonstrated that deletion of Notch2 with 
Prx1-Cre enhances bone formation in the long bones (31). Here, 
we recreated Prx1-Cre Notch2fl/fl (PN2) mutant mice by breed-
ing Prx1-Cre Notch2fl/+ males with Notch2fl/fl females. Reverse 
transcription quantitative PCR (RT-qPCR) analyses with total 
RNA extracted from cortical bone confirmed that Notch2 mRNA 
expression was reduced by 50% in the PN2 mice compared with 
expression in the Notch2fl/fl (N2) mice (Supplemental Figure 1; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI96221DS1). On the other hand, Nfatc1, a 
known target of the Hey transcriptional repressors, was upregu-
Table 1. μCT analyses of trabecular bone in proximal tibiae
Genotype BV/TV (%) Tb.N (1/mm) Tb.Th (mm) Tb.Sp (mm)
Notch2fl/fl/DMSO 18.1 ± 1.108 4.16 ± 0.335 0.0679 ± 0.002 0.240 ± 0.025
Notch2fl/fl/3PO 12.1 ± 2.661A 2.81 ± 0.537A 0.0613 ± 0.006A 0.365 ± 0.079A
Prx1-Cre Notch2fl/fl/DMSO 22.9 ± 0.694B 4.74 ± 0.279B 0.0716±0.005B 0.198 ± 0.016 B
Prx1-Cre Notch2fl/fl/3PO 12.5 ± 3.055C 3.31 ± 0.312C 0.0629 ± 0.005 C 0.303 ± 0.034C
Values represent the mean ± SD. Tb.N, number of trabeculae; Tb.Th, trabecular thickness; Tb.Sp, trabecular spacing. 
n ≥ 6 for each group. A,B,CP < 0.05, for statistically significant effects for A3PO, BCre, and C3PO-Cre interaction, as 
determined by 2-way ANOVA.
Table 2. μCT analyses of cortical bone in proximal tibiae
Genotype BV/TV (%) Tt.Ar (mm2) Ct.Ar (mm2) Ct.Ar/Tt.Ar (%) Cortical ThA (mm)
Notch2fl/fl/DMSO 62.6 ± 2.2 0.94 ± 0.09 0.59 ± 0.04 62.6 ± 2.2 0.20 ± 0.007
Notch2fl/fl/3PO 58.6 ± 2.6A 0.76 ± 0.10 0.45 ± 0.07A 58.6 ± 2.6A 0.17±0.018A
Prx1-Cre Notch2fl/fl/DMSO 64.8 ± 2.1 0.90 ± 0.07 0.58 ± 0.04 64.8 ± 2.2 0.21 ± 0.010
Prx1-Cre Notch2fl/fl/3PO 58.9 ± 3.1B 0.75 ± 0.11 0.44 ± 0.08B 58.9 ± 3.1B 0.17 ± 0.021B
Values represent the mean ± SD. Tt.Ar, total area; Ct.Ar, cortical area; Cortical Th, cortical thickness. n ≥ 6 for each group. A,BP < 0.05, for statistically 
significant effects for A3PO and B3PO-Cre interaction, as determined by 2-way ANOVA. 
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mal progenitor cell line derived from adult mice. The choice of 
the cell line allowed us to establish stable clones expressing either 
NICD2 or GFP (termed NICD2-ST2 or GFP-ST2 cells, respective-
ly) in response to doxycycline (Dox). Expression of NICD2, but 
not GFP, reduced both glucose consumption and lactate secretion 
by ST2 cells after 48 hours of Dox induction (Figure 3A). Seahorse 
analyses confirmed that induction of NICD2 for 48 hours sup-
pressed the extracellular acidification rate (ECAR), with or with-
out the mitochondria stressors (Figure 3B). NICD2 also reduced 
the oxygen consumption rate (OCR) in both basal conditions and 
in response to the uncoupling reagent FCCP (Figure 3C). Quan-
tification of the OCR data revealed a decrease in both ATP pro-
duction from mitochondrial respiration and the spare respiratory 
capacity upon NICD2 expression (Figure 3D). Biochemical mea-
surements revealed a notable reduction in steady-state intracel-
lular ATP levels in response to 48 hours of Dox treatment (Figure 
3E). In keeping with reduced glucose consumption, incubation of 
the cells with the fluorescent glucose analog 2-NBDG revealed 
that NICD2 began to suppress glucose uptake after 12 hours of 
Dox treatment (Figure 3F). Western blot analyses showed that 
(Figure 2H). On the other hand, 3PO did not significantly increase 
the levels of the C-terminal telopeptide of type I collagen (CTX-I) 
in  the serum of either N2 or PN2 mice, indicating a relatively small 
effect on bone resorption (Figure 2I). To confirm the direct effect 
of 3PO on osteoblast differentiation, we cultured primary BMSCs 
from PN2 and N2 mice on Jagged1-treated plates in osteogenic 
media with or without 3PO. Jagged1 suppressed the expression of 
the osteoblast markers Alpl, Ibsp, Runx2, and Bglap in N2 BMSCs 
but did not have a similar effect on PN2 BMSCs (Supplemental 
Figure 2). In fact, Jagged1 resulted in a slight increase in Alpl and 
Ibsp mRNA expression in the PN2 BMSCs for reasons unknown at 
present. Importantly, 3PO suppressed the expression of all markers 
in both N2 and PN2 BMSCs cultured with Jagged1, indicating that 
Pfkfb3 functionally interacts with Notch in regulating osteoblast 
differentiation in vitro (Supplemental Figure 2). Thus, both in vivo 
and in vitro evidence identifies Pfkfb3 as a key mediator for the 
suppression of osteoblast differentiation by Notch.
Canonical Notch signaling suppresses glycolysis. To gain further 
insights into the regulation of glucose metabolism, we chose to 
activate Notch signaling in ST2 cells, a bone marrow mesenchy-
Figure 3. Notch2 signaling suppresses glycolysis in ST2 cells. (A) Glucose consumption and lactate production by GFP-ST2 or NICD2-ST2 cells treated with 
vehicle or Dox for 48 hours. n = 3. (B–D) Seahorse analyses of NICD2-ST2 cells treated with vehicle or Dox for 48 hours. n = 10. (E) Relative ATP levels in 
NICD2-ST2 cells treated with vehicle or Dox for 48 hours. n = 6. (F) Glucose uptake assays in NICD2-ST2 cells treated with vehicle or Dox for the indicated 
durations. n = 6. (G) Western blots of NICD2-ST2 cells treated with vehicle or Dox for the indicated durations. β-Actin was used for normalization and quan-
tification (mean ± SD) was determined from 3 independent samples. After normalization to β-Actin, the levels in “-Dox” lanes were designated 1 and those 
in the “+Dox” lanes were further normalized. *P < 0.05, by 2-tailed Student’s t test (A and D–G).
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NICD2 reduced both Pfkfb3 and Ldha after 12 hours of induction 
(Figure 3G). Thus, as with Notch activation in the primary bone 
marrow mesenchymal cells, sustained Notch2 signaling in ST2 
cells suppressed glycolysis.
We next assessed the potential role of canonical Notch sig-
naling in the regulation of metabolism. Specifically, we tested 
the effect of dominant-negative Maml1 (dnMaml1), which has 
been well established as an inhibitor of the canonical Notch sig-
naling pathway (33). Retroviral expression of dnMaml1, but not 
GFP, completely eliminated the suppression of glucose consump-
tion by NICD2 and partially restored the production of lactate 
(Figure 4, A and B). Consistent with metabolic rescue, dnMaml1 
restored Pfkfb3 and Ldha expression to normal levels in response 
to NICD2 (Figure 4C). It is worth noting that dnMaml1 alone did 
not affect glucose consumption, lactate production, or the meta-
bolic enzymes, confirming the specific antagonism of dnMaml1 
on Notch2 signaling. Thus, Notch2 signaling suppresses glucose 
metabolism through a Maml1-dependent mechanism.
Given that the Hes/Hey transcriptional repressors are the 
prototypical mediators of canonical Notch signaling, we exam-
ined whether they were responsible for metabolic regulation. 
We focused on Hey1, as our earlier results showed that it was the 
most robustly induced by NICD2 among the Hes and Hey genes 
in BMSCs (Figure 1A). To this end, we generated a stable ST2 cell 
line expressing Hey1 in response to Dox. However, Hey1 expres-
sion did not affect glucose consumption or lactate production, 
Figure 4. Canonical Notch signaling suppresses glycolysis. (A–C) Effects of retroviral expression of GFP or dnMaml1 on glucose consumption (A), lactate 
production (B) or metabolic enzymes (C) in NICD2-ST2 cells treated with vehicle or Dox for 48 hours. β-Actin was used for normalization, and quantification 
(mean ± SD) was determined from 3 independent samples. After normalization to β-Actin, the level in the left-most lane is designated 1, and those of the 
other lanes are further normalized to the left-most lane. (D) Glucose consumption and lactate production in Hey1-ST2 cells treated with vehicle or Dox for 
48 hours. Western blot shows the induction of Flag-Hey1 by Dox. n = 3. (E) Relative mRNA levels of NFATc1 by RT-qPCR in Hey1-ST2 cells treated with vehi-
cle or Dox for 48 hours. n = 3. (F) RT-qPCR analyses of Hey1 in NICD2-ST2 cells infected with lentivirus expressing 2 different Hey1 shRNAs or the control 
luciferase shRNA (shLuc). (G) Glucose consumption and lactate production in NICD2-ST2 cells infected with lentivirus expressing different shRNAs, with 
or without Dox for 48 hours. (H) Relative glucose consumption in NICD2-ST2 cells infected with lentivirus expressing different shRNAs, with or without 
Dox for 48 hours. Glucose consumption was normalized to the protein amount and then to the vehicle-treated group designated as 1. (I) RT-qPCR analyses 
of mRNA levels showing shRNA knockdown efficiency. n = 3. *P = 0.05, by 2-way ANOVA followed by Bonferroni’s post hoc test (A, B, F, and I) or 2-tailed 
Student’s t test (C, E, G, and H).
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even though it suppressed the mRNA levels of NFATc1, which was 
previously identified as a Hey1 target gene (Figure 4, D and E) 
(31). To further test the potential relevance of Hey1, we knocked 
down its expression in NICD2-ST2 cells with shRNA expressed 
from a lentiviral vector. Whereas Dox markedly induced Hey1 in 
cells expressing the control shRNA targeting the luciferase gene 
(shLuc), 2 independent Hey1 shRNA constructs (Hey1_1 and 
Hey1_2) diminished the induction of Hey1 by more than 80% 
(Figure 4F). However, neither construct showed any effect on the 
suppression of glucose consumption or lactate secretion by Dox 
in NICD2-ST2 cells (Figure 4G). Therefore, induction of the Hes/
Hey proteins does not appear to be the main mechanism mediat-
ing metabolic regulation by Notch.
To gain further insights into the mechanism underlying glyco-
lytic suppression by Notch, we performed RNA-Seq experiments 
using NICD2-ST2 cells with or without Dox treatment for 24 hours. 
Among the genes with mRNA levels changed by a minimum of 
20%, the prototypical Notch target genes, including Hes1, Hes6, 
Hey1 and Hey2, were induced by NICD2. However, like that of 
Hey1, effective knockdown of Hey2, Hes1, or Hes6 did not alleviate 
the suppression of glucose consumption caused by NICD2 overex-
pression (Figure 4, H and I). Importantly, several suppressed genes 
encode glycolytic enzymes including Pfkfb2, Pfkfb3, Pfkfb4, Eno2, 
Eno3, and Ldha, while several others, such as Ndufaf2, Ndufc1, 
Ndufs5, and Ndufaf4 of complex I, and Ndufa4 of complex IV, 
code for components of the mitochondrial electron transport chain 
(ETC). RT-qPCR experiments confirmed the suppression of those 
genes by NICD2 (Supplemental Figure 3). Furthermore, dnMaml1, 
which was shown earlier to negate the metabolic effect of Notch, 
either abolished or alleviated the suppression of glycolytic or ETC 
genes by NICD2 (Figure 5, A and B). Thus, transcriptional suppres-
sion of both glycolytic and mitochondrial ETC genes may contrib-
ute to the restriction of glycolysis by Notch.
To explore the mechanism whereby canonical Notch signal-
ing suppresses metabolic gene expression, we investigated the 
potential role of transcriptional repressors beyond the Hes/Hey 
family. RNA-Seq experiments identified 14 additional known 
repressors that were induced by at least 2-fold and that had an 
Figure 5. Canonical Notch signaling suppresses gene expression of glycolytic enzymes and components of the mitochondrial ETC. (A and B) Relative 
mRNA levels of glycolytic enzymes (A) and components of the mitochondrial ETC (B) in NICD2-ST2 cells with retroviral expression of GFP or dnMaml1 and 
treatment with vehicle or Dox for 24 hours. (C) Relative glucose consumption in NICD2-ST2 cells infected with lentivirus expressing different shRNAs, as 
indicated, with or without Dox for 48 hours. Glucose consumption was normalized to the protein amount and then to the no-Dox control designated as 1. 
n = 3. *P < 0.05, by 2-way ANOVA followed by Bonferroni’s post hoc test (A and B) or 2-tailed Student’s t test (C).
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phosphorylation at Thr172 was reduced in ST2 cells upon NICD2 
expression for 12 or 48 hours and observed the same kinetics as 
that for the suppression of glucose uptake (Figure 6C, compare 
with Figure 3F). Importantly, dnMaml1, shown above to abolish 
the metabolic effect of NICD2, also restored the phosphorylation 
of AMPK and acetyl-coA carboxylase (ACC), a prototypical sub-
strate of AMPK (Figure 6, D and E). The suppression of AMPK by 
Notch was confirmed in WT BMSCs, as Jagged1 reduced the levels 
of phosphorylated AMPKα (p-AMPKα) and p-ACC (Figure 6F). To 
test the functional relevance of AMPK suppression to Notch func-
tion, we force-activated the enzyme with the AMP analog AICAR. 
At either 50 or 100 μM, AICAR did not affect basal glucose con-
sumption or lactate secretion by BMSCs but abolished the suppres-
sion by Jagged1 (Figure 6G). Likewise, 100 μM AICAR overcame 
the suppression of glucose consumption and lactate secretion by 
Dox-induced NICD2 expression in the NICD2-ST2 cells (Figure 
7A). However, AICAR had little to no effect on mRNA levels of the 
glycolytic genes that were suppressed by NICD2 (Figure 7B). Thus, 
we found that force-activation of AMPK was sufficient to counter-
act the glycolytic suppression by Notch, without affecting glyco-
lytic gene expression. This observation is consistent with previous 
reports that AMPK phosphorylates Pfkfb3 to increase its enzymat-
ic activity and hence glycolysis. Finally, to test whether the sup-
pression of complex I genes was sufficient to reduce AMPK activ-
ity, we knocked down Ndufaf2, which was suppressed by Notch, 
and assayed for AMPK phosphorylation. We found that 2 indepen-
dent shRNAs effectively reduced Ndufaf2 mRNA expression and 
decreased p-AMPKα levels relative to total AMPK levels (Figure 
7C). Taken together, the results support a model in which canoni-
cal Notch signaling induces multiple transcriptional repressors to 
suppress both glycolytic and mitochondrial ETC genes. Whereas 
the former reduces the abundance of glycolytic enzymes, the lat-
ter results in decreased AMPK activity that probably restricts the 
activity of the enzymes (Figure 8).
Discussion
We have provided evidence that Notch signaling suppresses glu-
cose metabolism in mesenchymal progenitors to inhibit osteo-
blast differentiation. The mechanism of the metabolic regulation 
by Notch involves the transcriptional downregulation of multiple 
metabolic genes integral to glycolysis or the mitochondrial ETC. 
The decrease in mitochondrial respiration in turn reduces ROS 
production and AMPK activity, resulting in further suppression 
of glycolysis. We believe that these results shed new light on the 
mechanism through which Notch regulates bone physiology.
Exactly how Notch signaling suppresses metabolic genes is 
not clear at present. The data clearly indicate the importance of 
the Maml proteins, thus implicating canonical Notch signaling 
in metabolic regulation. However, since the NICD-Maml-Rbpjk 
complex is known to activate gene expression, the gene suppres-
sion we observed must be indirect. Although Hes/Hey transcrip-
tion suppressors are prototypical mediators for Notch, they are 
unlikely to be the main driver for metabolic suppression, as over-
expression of Hey1 did not impair glycolysis, and knockdown of 
the relevant Hes/Hey genes did not blunt the Notch effect. On the 
other hand, 5 transcriptional repressors induced by NICD2 con-
tributed to the glycolytic suppression, but future experiments are 
induced level of more than 10 reads per kb per million mapped 
reads (RPKM) upon NICD2 expression over a 24-hour period in 
ST2 cells. RT-qPCR experiments confirmed the induction of the 
repressors by NICD2 after 24 hours and, further, that their induc-
tion was abolished by the viral expression of dnMaml1. We then 
systematically knocked down each repressor with 2 independent 
shRNAs in NICD2-ST2 cells and measured glucose consumption 
with or without Dox induction over a 48-hour period. The results 
showed that knockdown of Cbfa2t3, Hr, Lmcd1, Tcf7l2, or Nab1 
essentially eliminated glycolytic suppression by NICD2, whereas 
the other repressors did not have the same effect (Figure 5C and 
Supplemental Figure 4) (Table 3). Thus, it is likely that canonical 
Notch signaling induces the expression of multiple transcriptional 
repressors to suppress glycolysis.
Notch suppresses glycolysis through downregulation of AMPK 
activity. The suppression of complex I genes by Notch2 prompted 
us to examine the potential role of complex I in metabolic regula-
tion. NICD2 expression in response to Dox for 24 hours reduced 
the activity of complex I in NICD2-ST2 cells (Figure 6A). Con-
sistent with complex I being a major producer of mitochondrial 
superoxide, we found that NICD2 decreased the level of mito-
chondrial superoxide after 12 or 24 hours of Dox induction (Figure 
6B). These results are consistent with our earlier observation that 
NICD2 expression reduced overall oxygen consumption (Figure 
3C). Overall, Notch2 signaling suppresses mitochondrial respira-
tion and the production of ROS.
Recent studies have demonstrated that mitochondrial super-
oxide activates adenosine 5′-monophosphate–activated protein 
kinase (AMPK) through H2O2 (34). Because of the essential role of 
AMPK in cellular metabolism, we examined its potential relevance 
to glycolytic suppression by Notch. As a heterotrimeric kinase 
composed of α, β, and γ subunits, AMPK activation correlates with 
phosphorylation at Thr172 on the α subunit (35). We found that 
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cose metabolism is not known, they likely reflect the specific epi-
genetic landscape and signaling network in each cell type.
The current study further strengthens the link between bone 
formation and cellular metabolism. Previous studies have demon-
strated that Wnt, PTH, and Igf signaling stimulates glycolysis and 
glutamine catabolism while increasing bone accrual (36). Here, 
Notch suppressed osteoblast differentiation, at least in part through 
the restriction of glucose metabolism. Together, these findings indi-
cate that metabolic rewiring plays an integral role in the regulation of 
bone formation and, further, that targeting metabolic pathways may 
be a promising avenue for the development of novel bone therapies.
Methods
Mouse strains. Notch2fl/fl, R26-NICD2, and Prx1-Cre mouse strains 
were generated as previously described  (30, 37, 38). We thank Ryuichi 
Nishinakamura (Kumamoto University, Japan) for providing the R26-
NICD2 mouse strain. All mice were housed in a specific pathogen–free 
(SPF) barrier facility managed by the Department of Comparative 
Medicine of Washington University. The animals were group housed 
under a 12-hour light cycle (6 am–6 pm) and fed standard chow (Pico-
Lab Mouse Diet 20, product 5058).
necessary to establish the potential direct suppression of glycolytic 
or ETC genes by any of the repressors implicated here.
The current study highlights the fact that metabolic regula-
tion by Notch is highly dependent on cellular context. A previous 
study has shown that Notch induces the transcription of Glut1, 
hexokinase A (Hex-A), and Impl3 (Ldha homolog) in Drosophila 
cells, resulting in a Warburg-like effect (27). However, RNA-Seq 
detected no change in Glut1, Hk1, or Hk2 upon expression of 
NICD2 in ST2 cells. On the contrary, we observed a downregula-
tion of Ldha and other key glycolytic enzymes and, consequently, 
a suppression of glycolysis by Notch. Another study using mouse 
macrophages indicated that Notch stimulates mitochondrial oxi-
dative phosphorylation in part through the transcriptional induc-
tion of pyruvate dehydrogenase phosphatase catalytic subunit 1 
(Ppd1) to promote the M1 phenotype (29). However, we observed 
a notable decrease in both Pdp1 (–1.7-fold) and Pdp2 (–2.6-fold) in 
ST2 cells after 24 hours of NICD2 expression. On the other hand, 
our finding about the suppressive role of Notch in glucose metabo-
lism is reminiscent of that previously reported in endothelial cells, 
in which Notch reduced Pfkfb3 and glycolytic flux (28). Overall, 
although the exact reason for the different effects of Notch on glu-
Figure 6. Notch suppresses glycolysis through downregulation of AMPK activity. (A–C) Measurements of mitochondrial complex I activity (n = 4) (A), 
mitochondrial superoxide levels (n = 6) (B), and p-AMPKα levels (n = 3) (C) in NICD2-ST2 cells treated with vehicle or Dox for the indicated durations. Total 
AMPKα was used for normalization, and quantification (mean ± SD) was determined from 3 independent samples. After normalization to total AMPKα, 
the level in the left lane was designated 1 and that of the right lane was further normalized to the left lane. mOD, mitochondrial OD. (D and E) Western 
blot analyses of NICD2-ST2 cells with retroviral expression of GFP or dnMaml1 and treatment with vehicle or Dox for 24 hours. Phosphorylation levels were 
normalized to total AMPKα or ACC, and quantification (mean ± SD) was determined from 3 independent samples. After normalization to total protein, the 
level in the left-most lane was designated 1 and the other lanes were further normalized to that lane. (F) Western blots of BMSCs with or without Jagged1 
stimulation for 24 hours. Normalization and quantification were determined as in D and E. (G) Effects of AICAR at the indicated concentration for 48 hours 
on glucose consumption and lactate production in BMSCs with or without Jagged1 stimulation. n = 3. *P < 0.05, by 2-tailed Student’s t test (A–G).
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NEC495A001MC) at 10 μCi per 20 g body weight and then sacrificed 
after 2 hours for collection of tibiae and femurs. The growth plates 
were surgically removed with a scalpel under the microscope before 
the bone marrow was cleared through centrifugation. The remaining 
trabecular and cortical bone was weighed, chopped with surgical scis-
sors, and then lysed in RIPA buffer for 30 minutes on ice. After centrif-
ugation, the supernatant was collected for scintillation counting.
Serum biochemical assays. For serum CTX-I or P1NP assays, serum 
was collected through retro-orbital bleeding from mice starved for 
6 hours, and the serum was analyzed with the RatLaps ELISA Kit 
(Immunodiagnostic Systems Ltd., AC-06F1) or the Rat/Mouse PINP 
EIA Kit (Immunodiagnostic Systems Ltd., AC-33F1) according to the 
manufacturers’ instructions.
Western blot analysis. ST2 cells or mouse primary BMSCs were har-
vested in lysis buffer (50 mM TrisCl, 150 mM NaCl, 1% NP-40, 5 mM 
EDTA, 5% glycerol) containing proteinase inhibitors and phosphatase 
inhibitors (Thermo Fisher Scientific, catalog 78442). To extract bone 
proteins, femurs and tibiae were pulverized in liquid nitrogen after 
surgical removal of the epiphysis and flushing of the marrow. The 
bone powders were harvested in the lysis buffer and centrifuged to 
collect the soluble proteins that were later quantified with the Micro 
BCA Protein Assay Kit (Thermo Fisher Scientific). Total protein (10 μg) 
Analyses of bone. For 3PO treatment, mice were injected i.p. with 
the chemical (MilliporeSigma, 525330) dissolved in DMSO at 50 mg/
kg body weight or an equal volume of DMSO as a control daily begin-
ning on P24 for 4 weeks. Micro-CT (μCT 40, Scanco Medical AG) 
was performed on tibiae. Quantification of the cancellous bone was 
assessed by measuring 100 μCT slices (1.6 mm) immediately below 
the growth plate, with a threshold of 200. For cortical bone parame-
ters, 50 μCT slices (0.8 mm) from the mid-shaft of the tibia were ana-
lyzed, with a threshold of 260.
For dynamic histomorphometry, calcein (MilliporeSigma) dis-
solved in water (pH 7.2–7.4, adjusted with NaOH) was injected i.p. at 
7.5 mg/kg body weight on days 7 and 2, respectively, prior to sacrifice. 
Bones were fixed in 70% ethanol, embedded in methyl-methacrylate, 
and sectioned at 10-μm thickness. Histomorphometric parameters 
were acquired with a BIOQUANT Osteo II from 3 sections per mouse 
and 3 mice for each genotype.
In vivo glucose uptake assay. Mice injected with 3PO or DMSO 
vehicle for 4 weeks were first examined for serum glucose levels. For 
this, blood samples were collected through the tail vein after the mice 
were starved for 3 hours, and blood glucose levels were measured 
with a glucose meter (Ascensia Contour; Bayer). The mice were rested 
for 30 minutes before being injected i.p. with 14C-2DG (PerkinElmer, 
Figure 7. AMPK activation rescues metabolic inhibition by Notch2 without restoring glycolytic gene expression. (A) Effects of AICAR for 48 hours on 
glucose consumption and lactate production in NICD2-ST2 cells. (B) RT-qPCR analyses of relative mRNA levels of glycolytic genes. (C) Western blot and RT- 
qPCR analyses of ST2 cells infected with lentivirus expressing shRNAs targeting luciferase (Luc) or Ndufaf2. pAMPK was first normalized to total AMPK in 
each lane. The normalized level in the left -most lane was designated 1 and those of the other lanes were further normalized to that lane. All RT-qPCR data 
were normalized to 18S rRNA. n = 3. *P < 0.05, by 2-way ANOVA followed by Bonferroni’s post hoc test (A) or 2-tailed Student’s t test (B and C).
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plasmid 20342), TetO-FUW-FlagNICD2-IRES-EGFP or TetO-FUW-
FlagHey1-IRES-EGFP, together with psPAX2 and pMD2.G. After over-
night incubation, the cells we placed into fresh media that was then 
harvested for viruses after 2 days.
To produce the stable cell lines, ST2 cells were coinfected with the 
FUW-M2rtTA virus, together with either the TetO-FUW-FlagNICD2-
IRES-EGFP or the TetO-FUW-FlagHey1-IRES-EGFP virus. The cells 
were then plated at single-cell density in 96-well plates for colony 
selection. The positive clones were identified on the basis of green 
fluorescence expression and Western blotting in the presence of Dox.
Cell culture. ST2 cells and BMSCs were grown in αMEM (Gib-
co, Thermo Fisher Scientific), and 293T cells were grown in DMEM 
was resolved by electrophoresis on Mini-PROTEAN TGX Precast 
Gel (Bio-Rad), transferred onto a 0.45-μm pore PVDF Immobilon-P 
membrane (MilliporeSigma), and detected with a specific antibody 
against Ldha (product no. 2012), AMPKα (product no. 2531), p-AMPKα 
(product no. 2532), β-actin (product no. 4970), Pkm2 (product no. 
4053), p-ACC (product no. 3661), or ACC (product no. 3676) (all pur-
chased from Cell Signaling Technology); or an antibody against Pfkfb4 
(product no. PAB4031) from Novus Biologicals; or Pkm1 (product no. 
SAB4200094) from MilliporeSigma. Membranes were blocked for 1 
hour at room temperature in 5% BSA (Roche) or 5% milk (Bio-Rad) in 
TBS containing 0.1% Tween-20 (TBST), followed by overnight incu-
bation at 4°C with the primary antibody. Then, the membranes were 
washed with TBST and further incubated at room temperature for 1.5 
hours with an HRP-conjugated anti-rabbit (GE Healthcare, product 
no. NA934V) or anti-mouse (Cell Signaling Technology, product no. 
7076S) secondary antibody. All blots were developed using the Clari-
ty Substrate Kit (Bio-Rad). Gel images were captured with ChemiDoc 
(Bio-Rad). Each experiment was repeated with a minimum of 3 inde-
pendently prepared protein samples.
Generation of Dox-inducible stable cell lines. To generate the TetO-
FUW-FlagNICD2-IRES-EGFP lentiviral construct, we first created the 
vector TetO-FUW-polylinker by replacing cMYC in the TetO-FUW-
cMYC plasmid (Addgene plasmid 20324) with a polylinker containing 
EcoRI, AscI, AsisI, AfeI, PacI, SwaI, SbfI, and XbaI. We then released 
3xFlag-NICD2 from p3xFlag-CMV-NICD2(Met1669-Ala2470) with 
EcoRI and SmaI and inserted it into the EcoRI and AfeI sites of TetO-
FUW-polylinker (39). Subsequently, IRES-EGFP amplified by PCR 
from pCIG was inserted into the PacI and XbaI sites of the polylinker to 
produce the final construct TetO-FUW-FlagNICD2-IRES-EGFP (40).
To make the TetO-FUW-FlagHey1-IRES-EGFP plasmid, we 
first inserted Hey1 cDNA into the XbaI and BamHI sites of p3xFlag-
CMV-7 (MilliporeSigma) to produce p3xFlag-CMV-Hey1. We then 
released 3xFlag-Hey1 from p3xFlag-CMV-Hey1 with EcoRI and SmaI 
and inserted it into the EcoRI and AfeI sites of TetO-FUW-polylinker. 
Finally, IRES-EGFP was inserted in the same way as described above.
Lentiviruses were produced according to a standard protocol. 
Briefly, 293T cells were transfected with FUW-M2rtTA (Addgene 
Figure 8. Working model for Notch signaling in the suppres-
sion of glucose metabolism in mesenchymal progenitors. 
Canonical Notch signaling induces multiple transcriptional 
repressors that suppress the transcription of genes encoding 
glycolytic enzymes or mitochondrial complex I components. 
The decrease in mitochondrial respiration lowers AMPK activ-
ity and helps to reduce glycolysis.
Table 4. Primers used for RT-qPCR
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D-9891). In some experiments, the cells were infected with dnMaml1- 
or GFP-expressing retroviruses for 8 hours and recovered in regular 
media overnight before being seeded overnight for Dox treatment. 
The retroviral plasmids MSCV-DNMAML1-GFP and MSCV-GFP 
were provided by Jon Aster (Brigham and Women’s Hospital, Boston, 
Massachusetts, USA) (41). To test the effect of Jagged1, the cell cul-
ture plates were first coated overnight at room temperature with 50 
μg/ml protein G (Thermo Fisher Scientific, 10-1201) in Dulbecco’s 
phosphate-buffered saline (DPBS) (Life Technologies, Thermo Fish-
er Scientific). The plates were then washed 3 times with DPBS and 
blocked with 10 mg/ml BSA in DPBS for 2 hours at room temperature. 
The blocked plates were then washed with DPBS and incubated with 
recombinant Jagged1-Fc (R&D Systems, 1277-JG) or CromPure IgG 
(Gibco, Thermo Fisher Scientific), both supplemented with 10% heat- 
inactivated FBS and penicillin-streptomycin. BMSCs were isolated 
from tibiae and femurs of 2-month-old mice. Briefly, the bones were 
cleanly dissected and the epiphysis cleared off with scissors. Bone 
marrow cells were collected from the bones by centrifugation and then 
incubated with RBC lysis buffer (MilliporeSigma, R7757-100ML). 
The remaining cells were then passed through a 70-μm cell strainer 
before being seeded onto a tissue culture plate in α-MEM contain-
ing 10% FBS. After daily changes of the medium for 3 days, the cells 
were allowed to grow until they reached confluence. The cells were 
then dissociated and seeded onto 24-well plates for experiments. For 
the Dox-inducible experiments in ST2 cells, the cells were incubated 
overnight before treatment with 500 ng/ml Dox (MilliporeSigma, 
Table 5. shRNA targeting sequences
Gene name TRC number shRNA ID code Sequence (5′–3′)
Cbfa2t3 TRCN0000096429 1 CCGGGCAAACAAGCTACTTAGAAATCTCGAGATTTCTAAGTAGCTTGTTTGCTTTTTG
  TRCN0000096430 2 CCGGCGACAAGAAGAAGTGATTGATCTCGAGATCAATCACTTCTTCTTGTCGTTTTTG
Hr TRCN0000085998 1 CCGGCCGTTCTACAAATATCTCTTTCTCGAGAAAGAGATATTTGTAGAACGGTTTTTG
  TRCN0000086000 2 CCGGGCAGGTAGTAGAACGGAAGATCTCGAGATCTTCCGTTCTACTACCTGCTTTTTG
Msx1 TRCN0000070623 1 CCGGCCATGTAGGCTACAGCATGTACTCGAGTACATGCTGTAGCCTACATGGTTTTTG
  TRCN0000070627 2 CCGGGCCTCACTCTACAGTGCCTCTCTCGAGAGAGGCACTGTAGAGTGAGGCTTTTTG
Zfp703 TRCN0000256674 1 CCGGGACCTGACACATCCAATTAAACTCGAGTTTAATTGGATGTGTCAGGTCTTTTTG
  TRCN0000256675 2 CCGGCTCCAGTGTCACCCTACAAACCTCGAGGTTTGTAGGGTGACACTGGAGTTTTTG
Foxs1 TRCN0000433258 1 CCGGGTAGGGCTCCTGTCAACTGTTCTCGAGAACAGTTGACAGGAGCCCTACTTTTTTG
  TRCN0000084998 2 CCGGCAAAGAGATGTGCTCGGCAAACTCGAGTTTGCCGAGCACATCTCTTTGTTTTTG
Lmcd1 TRCN0000098786 1 CCGGCCTGCAGTACATGGAACTCATCTCGAGATGAGTTCCATGTACTGCAGGTTTTTG
  TRCN0000098789 2 CCGGCCGTGCGTACATCGTCACCAACTCGAGTTGGTGACGATGTACGCACGGTTTTTG
Nfatc4 TRCN0000075340 1 CCGGGCCAGACTCTAAAGTGGTGTTCTCGAGAACACCACTTTAGAGTCTGGCTTTTTG
  TRCN0000075341 2 CCGGCGAGGTGGAGTCTGAACTTAACTCGAGTTAAGTTCAGACTCCACCTCGTTTTTG
Btg2 TRCN0000231223 1 CCGGATGGCCGTCTCCAGCTAGATACTCGAGTATCTAGCTGGAGACGGCCATTTTTTG
  TRCN0000231220 2 CCGGGCGAGCAGAGACTCAAGGTTTCTCGAGAAACCTTGAGTCTCTGCTCGCTTTTTG
Cobra1 TRCN0000126520 1 CCGGCCTGAGAGTTTCACCAAGTTTCTCGAGAAACTTGGTGAAACTCTCAGGTTTTTG
  TRCN0000126519 2 CCGGCCTGATATTCAATCTGCACAACTCGAGTTGTGCAGATTGAATATCAGGTTTTTG
Brms1 TRCN0000039282 1 CCGGACGACAAACTACATAGCAGAACTCGAGTTCTGCTATGTAGTTTGTCGTTTTTTG
  TRCN0000039281 2 CCGGGCTCGTTTCTGGTCCATACATCTCGAGATGTATGGACCAGAAACGAGCTTTTTG
Tle1 TRCN0000236783 1 CCGGGGCACAGATAAGCGCAGAAATCTCGAGATTTCTGCGCTTATCTGTGCCTTTTTG
  TRCN0000236782 2 CCGGGATCTTCTCTTTGGGATATTGCTCGAGCAATATCCCAAAGAGAAGATCTTTTTG
Bach1 TRCN0000084279 1 CCGGGCGTACACAATATCGAGGAATCTCGAGATTCCTCGATATTGTGTACGCTTTTTG
  TRCN0000288208 2 CCGGGCTCGACTGTATCCATGACATCTCGAGATGTCATGGATACAGTCGAGCTTTTTG
Tcf7l2 TRCN0000012180 1 CCGGGCTGACAGTCAACGCATCTATCTCGAGATAGATGCGTTGACTGTCAGCTTTTT
  TRCN0000012178 2 CCGGCCTTAGCGTAAGCATCTTATACTCGAGTATAAGATGCTTACGCTAAGGTTTTT
Nab1 TRCN0000096136 1 CCGGGTGGTGAAAGAGATGAATTATCTCGAGATAATTCATCTCTTTCACCACTTTTTG
  TRCN0000351197 2 CCGGGTGGTGAAAGAGATGAATTATCTCGAGATAATTCATCTCTTTCACCACTTTTTG
Ndufaf2 TRCN0000265502 1 CCGGACTACTACGTCGCCGAGTACACTCGAGTGTACTCGGCGACGTAGTAGTTTTTTG
  TRCN0000254242 2 CCGGCCTACTGCAACTCAAGTTAAACTCGAGTTTAACTTGAGTTGCAGTAGGTTTTTG
Hey1  1 GCCCGTTATCTGAGCATCATT
   2 AGACCGAATCAATAACAGTTT
Hey2  1 GCCAGAAAGATGAAGGGAAAT
   2 CCACCTCTCTTCTGTCTCTTT
Hes1  1 TGAAAGTCTAAGCCAACTGAA
   2 CCAGCCAGTGTCAACACGACA
Hes6  1 CCTGAAAGGAAGTTCAGATTT
   2 TGGTGTCTACATCCTTAGGCA
shLuc   CAGAATCGTCGTATGCAGTGA
TRC, The RNAi Consortium. 
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103015-100) were prepared in XF assay medium at final concentra-
tions of 5 mM for oligomycin and 1 mM for the rest. At the end of the 
assays, protein concentrations were measured for normalization of the 
OCR and ECAR.
Measurement of mitochondrial superoxide and mitochondrial com-
plex I activity. For mitochondrial superoxide measurements, NICD2-
ST2 cells were seeded in 96-well black wall tissue culture plates (Corn-
ing, 3904) and treated with vehicle or Dox for 6, 12, or 24 hours. The 
cells were then treated with the MitoSOX Red mitochondrial superox-
ide indicator (Molecular Probes, Thermo Fisher Scientific, M36008) 
at 5 μM for 10 minutes at 37°C, washed 3 times with DPBS, and mea-
sured at 510/580 nm with a plate reader (BioTek). The fluorescence 
intensity was normalized to the DNA content. Mitochondrial complex 
I activity was measured with the Complex I Enzyme Activity Micro-
plate Assay Kit (Colorimetric) (Abcam, ab109721).
shRNA knockdown. Lentiviruses expressing shRNA were pro-
duced by transfecting HEK293T cells with pLKO.1 shRNA plasmids 
(Genome Center at Washington University) and the packaging plas-
mids pMD2.G and psPAX2 using Fugen6 transfection reagent (Prome-
ga). The viral media were added to the cells for 8 hours before being 
replaced with fresh growth media for an additional 48 hours. After 
treatment with Dox for 24 hours, the cells were harvested for RNA iso-
lation and RT-qPCR. For glucose consumption and lactate production 
assays, the cells were harvested 48 hours after Dox treatment. shRNA 
targeting sequences are listed in Table 5.
Statistics. Statistical significance was calculated with either a 
2-tailed Student’s t test or a 2-way ANOVA. A P value of less than 0.05 
was considered significant.
Study approval. The studies in mice were reviewed and approved 
by the IACUC of Washington University.
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Fc (Jackson ImmunoResearch, 009-000-008) at a concentration of 
2 μg/ml in 0.1% BSA and PBS for 4 hours at room temperature. After 
washing 3 times with DPBS, the cells were immediately seeded onto 
the coated plates in the appropriate medium, as described above for 
each cell type.
RNA isolation, RT-qPCR, and RNA-Seq. Total RNA was isolated 
from NICD2-ST2 cells or BMSCs with the RNeasy Mini Kit (QIAGEN, 
74104). Reverse transcription was performed with 400 ng total RNA 
and iScript Reverse Transcription Supermix (Bio-Rad, 1708891). 
qPCR was performed with an ABI StepOne Plus machine in a 96-well 
format using SsoAdvanced Universal CYBR Green Supermix (Bio-
Rad, 1725274). Primer sequences are listed in Table 4. 18S rRNA was 
used as an internal control, and relative expression was calculated by 
the 2–ΔΔCt method.
For RNA-Seq experiments, NICD2-ST2 cells were treated with 
vehicle or 500 ng/ml Dox for 24 hours before isolation of total RNA. 
Poly-A RNA was isolated from 20 μg total RNA using Oligo-dT beads 
[Dynabeads Oligo(dT)25, Thermo Fisher Scientific] and used to gener-
ate the PCR-amplified cDNA library, which was then sequenced with 
the Illumina HiSeq 2000 as single reads extending 42 bases (Genome 
Technology Access Center [GTAC], Washington University School of 
Medicine). The raw data were demultiplexed and aligned to the refer-
ence genome (mm9) using TopHat. The Partek Genomic Suite was used 
to assemble transcripts and analyze their expression. The RNA-Seq data 
were deposited in the NCBI’s BioProject database (ID PRJNA488100).
Metabolite measurements. Subconfluent NICD2-ST2 cells grow-
ing in αMEM containing 10% FBS were treated with vehicle or 500 
ng/ml Dox for 12, 24, or 48 hours. Glucose consumption and lactate 
production were measured with the Glucose (HK) Assay Kit (Milli-
poreSigma, GAHK20) and the L-lactate Assay Kit (Eton biosciences, 
1200011002). ATP was measured in cell lysates with the Cell Titer-
Glo Luminescent Cell Viability Assay Kit (Promega, G7573 ). For glu-
cose uptake assays, the cells were incubated with 100 μM 2-NBDG 
for 1 hour, and fluorescence intensity was measured according to the 
manufacturer’s instructions (Glucose Uptake Cell-Based Assay Kit, 
Cayman Chemical, 600470).
Seahorse extracellular flux assays. NICD2-ST2 cells were plated at 
5,000 cells/well in XF96 plates coated with Cell-Tak (BD Bioscienc-
es). On the next day, the cells were treated with 500 ng/ml Dox for 
48 hours with or without inhibitors for the indicated durations before 
switching to the assay medium (Seahorse Bioscience, 101022-100, 
or MilliporeSigma, D5030-1L) and further incubation in a CO2-free 
incubator for 1 hour. Oligomycin (ATP synthase inhibitor), carbonyl 
cyanide p-triﬂuoromethoxyphenylhydrazone (FCCP; proton iono-
phore), antimycin A (complex III inhibitor), and rotenone (complex I 
inhibitor) (Seahorse XF Cell Mito Stress Test Kit, Seahorse Bioscience, 
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